Risk factors for coronary artery disease in patients with renal failure

被引:25
作者
Prichard, S [1 ]
机构
[1] McGill Univ, Ctr Hlth, Royal Victoria Hosp, Div Nephrol, Montreal, PQ H3A 1A1, Canada
关键词
cardiovascular risk factors; coronary artery disease; hypertension; diabetes mellitus; dyslipidemia; homocysteine; inflammation; oxidant stress;
D O I
10.1097/00000441-200304000-00007
中图分类号
R5 [内科学];
学科分类号
1002 [临床医学]; 100201 [内科学];
摘要
Cardiovascular mortality is markedly increased in patients with end-stage renal disease (ESRD), particularly those receiving dialysis. Coronary artery disease is the most important cause of death in these patients. As in the general population, older age, male gender, and the postmenopausal state in women are cardiovascular risk factors in patients with ESRD. However, hypertension, diabetes mellitus, and dyslipidemia, known to promote cardiovascular disease in the general population, are particularly likely to do so in patients with ESRD because of their high prevalence in this population. In addition, nontraditional cardiovascular risk factors such as hyperhomocystinemia, inflammation, elevated calcium X phosphate product, endothelial dysfunction, and oxidant stress, occur frequently in patients with ESRD. Vigorous treatment of modifiable cardiovascular risk factors has reduced cardiovascular risk in patients without ESRD. The extent to which such risk factor modification would alter cardiovascular risk in ESRD remains uncertain.
引用
收藏
页码:209 / 213
页数:5
相关论文
共 31 条
[1]
Oral L-arginine does not improve endothelial dysfunction in children with chronic renal failure [J].
Bennett-Richards, KJ ;
Kattenhorn, M ;
Donald, AE ;
Oakley, GR ;
Varghese, Z ;
Bruckdorfer, KR ;
Deanfield, JE ;
Rees, L .
KIDNEY INTERNATIONAL, 2002, 62 (04) :1372-1378
[2]
Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study [J].
Block, GA ;
Hulbert-Shearon, TE ;
Levin, NW ;
Port, FK .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (04) :607-617
[3]
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial [J].
Boaz, M ;
Smetana, S ;
Weinstein, T ;
Matas, Z ;
Gafter, U ;
Iaina, A ;
Knecht, A ;
Weissgarten, Y ;
Brunner, D ;
Fainaru, M ;
Green, MS .
LANCET, 2000, 356 (9237) :1213-1218
[4]
HYPERHOMOCYSTEINEMIA AND TRADITIONAL CARDIOVASCULAR-DISEASE RISK-FACTORS IN END-STAGE RENAL-DISEASE PATIENTS ON DIALYSIS - A CASE-CONTROL STUDY [J].
BOSTOM, AG ;
SHEMIN, D ;
LAPANE, KL ;
MILLER, JW ;
SUTHERLAND, P ;
NADEAU, M ;
SEYOUM, E ;
HARTMAN, W ;
PRIOR, R ;
WILSON, PWF ;
SELHUB, J .
ATHEROSCLEROSIS, 1995, 114 (01) :93-103
[5]
Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes [J].
Bostom, AG ;
Lathrop, L .
KIDNEY INTERNATIONAL, 1997, 52 (01) :10-20
[6]
Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients [J].
Braun, J ;
Oldendorf, M ;
Moshage, W ;
Heidler, R ;
Zeitler, E ;
Luft, FC .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :394-401
[7]
Coronary artery disease: Improved reproducibility of calcium scoring with an electron-beam CT volumetric method [J].
Callister, TQ ;
Cooil, B ;
Raya, SP ;
Lippolis, NJ ;
Russo, DJ ;
Raggi, P .
RADIOLOGY, 1998, 208 (03) :807-814
[8]
Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients [J].
Chertow, GM ;
Burke, SK ;
Raggi, P .
KIDNEY INTERNATIONAL, 2002, 62 (01) :245-252
[9]
Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[10]
Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency [J].
Culleton, BF ;
Larson, MG ;
Wilson, PWF ;
Evans, JC ;
Parfrey, PS ;
Levy, D .
KIDNEY INTERNATIONAL, 1999, 56 (06) :2214-2219